Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alström Syndrome, a Rare Obesity Syndrome
Tirzepatide shows great effectiveness with regard to body weight, MASLD, and insulin resistance in AS. Follow-up studies with larger cohorts have to be performed to confirm these findings.
Authors
- Alexandra Kautzky‐Willer (ORCID: https://orcid.org/0000-0002-3520-4105)
- Thomas Scherer (ORCID: https://orcid.org/0000-0003-4980-706X)
- Moritz Ferch (ORCID: https://orcid.org/0000-0001-7786-8156)
- Michael Krebs (ORCID: https://orcid.org/0000-0002-9265-7274)
- Susanne Greber‐Platzer (ORCID: https://orcid.org/0000-0002-3706-8370)
- Albert Friedrich Stättermayer (ORCID: https://orcid.org/0000-0003-0737-4091)
- Isabel Peitsch
Institutions
- Medical University of Vienna (AT)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1210/clinem/dgaf258
- Citations
- 6
- Primary Topic
- Genetic Syndromes and Imprinting
- Type
- article
- Field-Weighted Citation Impact
- 10.90